Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

Trevi Therapeutics (Nasdaq: TRVI) announced management will participate in the Stifel 2025 Healthcare Conference in New York on November 11–12, 2025.

Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI) announced management will participate in the Stifel 2025 Healthcare Conference in New York on November 11–12, 2025.

A fireside chat featuring Jennifer Good, President and CEO, and James Cassella, Ph.D., Chief Development Officer, is scheduled for Tuesday, November 11, 2025 at 3:20 p.m. ET. Company executives will also hold investor meetings with conference attendees. The fireside chat and meetings will be available for in-person attendees.

Argus Nov 4 session

+1.50% close to close 0.6x rel. volume Open Argus

Details

News Market Reaction – TRVI

On Nov 4, the day this news came out, TRVI closed 1.50% above the previous close.

Data tracked by StockTitan Argus for the Nov 4 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Fireside Chat with Management on Tuesday, November 11, 2025, at 3:20 p.m. ET

NEW HAVEN, Conn., Nov. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and James Cassella, Ph.D., Chief Development Officer, will participate in a fireside chat at the Stifel 2025 Healthcare Conference on Tuesday, November 11, at 3:20 p.m. ET. Held from November 11-12 in New York, Ms. Good and Dr. Cassella will also participate in investor meetings with attendees at the event. This fireside chat and meetings will be available for in-person attendees.

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.

Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~150,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.   

Refractory chronic cough is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.  

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. 

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn. 

Investor Contact 
Jonathan Carlson 
Trevi Therapeutics, Inc. 
(203) 654 3286 
carlsonj@trevitherapeutics.com  

Media Contact 
Rosalia Scampoli 
914-815-1465 
rscampoli@marketcompr.com  

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-stifel-2025-healthcare-conference-302602653.html

SOURCE Trevi Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Trevi Therapeutics (TRVI) present at the Stifel 2025 Healthcare Conference?

Trevi will participate on November 11–12, 2025, with a fireside chat on November 11 at 3:20 p.m. ET.

Who will represent Trevi Therapeutics (TRVI) at the Stifel 2025 Healthcare Conference?

Jennifer Good, President and CEO, and James Cassella, Ph.D., Chief Development Officer, will participate.

Will the Trevi (TRVI) fireside chat at Stifel 2025 be available virtually?

The announcement states the fireside chat and meetings will be available for in-person attendees only.

What topics will Trevi (TRVI) executives likely discuss at the Stifel 2025 fireside chat?

Executives are expected to discuss company developments, clinical programs, and investor updates related to Trevi's programs.

Can investors request one-on-one meetings with Trevi (TRVI) at the Stifel 2025 Healthcare Conference?

Yes, Trevi management will participate in investor meetings with conference attendees during the event.

Where and when is the Stifel 2025 Healthcare Conference taking place for Trevi (TRVI)?

The conference is held in New York from November 11–12, 2025, with Trevi's session on November 11 at 3:20 p.m. ET.